• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers launch early-stage trial for nasal flu vaccine

September 18, 2018 By Sarah Faulkner

National Institutes of Health logoResearchers at St. Louis University reported that an early-stage trial testing an experimental nasal flu vaccine in children and teens began enrolling participants this week.

In the 50-person study, half of the participants will receive the investigational nasal vaccine and the other half will receive an inactive saline solution. All of the study’s participants are slated to receive an intramuscular injection of a quadrivalent seasonal flu vaccine three months following the initial dose of nasal vaccine or placebo.

Researchers are trying to understand if the combination of the quadrivalent seasonal flu vaccine and the investigational nasal vaccine will lead to broader protection against flu viruses compared to the quadrivalent vaccine alone. Researchers plan to assess the participants’ blood samples four times following the initial vaccination and three weeks after the second vaccination.

The Phase I trial is being conducted at a Vaccine and Treatment Evaluation Unit site at the university, funded by the NIH’s National Institute of Allergy and Infectious Diseases.

The experimental nasal vaccine, made by FluGen, was developed from a strain of seasonal flu virus that has been genetically modified to replicate just once in the body, according to the NIH. This feature stops the virus from causing disease, but triggers the body into producing an immune response. Researchers predict that volunteers who receive the experimental vaccine will be protected against an array of flu viruses.

“We are hopeful that newer kinds of influenza vaccines, such as the candidate being tested in this trial, will provide protection even if their components do not precisely match the currently circulating influenza virus strains,” NIAID director Dr. Anthony Fauci said in prepared remarks.

A Phase II trial of the vaccine in healthy adults is also underway.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Pharmaceuticals Tagged With: flugen, National Institutes of Health

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS